Data from this work and others would suggest that persister populations from Gorlin patients as well as mouse models of BCC tumor persistence enter an LY6D+/IFE-like state with SMOi but then return to GLI1+/HH-dependent state after stopping therapy and not an SCC-like state20. The gene discussed is LY6D; the disease is skin basal cell carcinoma.